Association of osteopontin promoter polymorphism and aggresivness in breast cancer | ||||
| Sohag Medical Journal | ||||
| Article 53, Volume 22, Issue 1, January 2018, Page 375-379 PDF (76.82 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/smj.2018.42049 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Madeha M. Zakhary1; Aida A. Mahmoud2; Wael B. Ahmed3; Marwa shaaban Hashim4 | ||||
| 1Department, of Medical Biochemistry, Faculty of Medicine, Assuit university. | ||||
| 2Department, of Medical Biochemistry, Faculty of Medicine, Sohag university. | ||||
| 3Department of General Surgery, Faculty of Medicine, Sohag university. | ||||
| 4Department of Biochemistry and microbiology, Facaulty of Medicine, Sohag University. | ||||
| Abstract | ||||
| Osteopontin (OPN) is an extracellularmatrix protein that is overexpressed in various cancers and promotes oncogenic features including cell proliferation, survival, migration, and angiogenesis, among others. OPN can participate in the regulation of the tumor microenvironment, affecting both cancer and neighboring cells. Here, we review The role of single-nucleotide polymorphism (SNP)-443 of the OPN gene in cancer aggressiveness. | ||||
|
Supplementary Files
|
||||
| References | ||||
|
1. Wood L.D., Parsons D.W., Jones S. et al.(2007)"The genomic landscapes of human breast and colorectal cancers". Science 318:1108–1113.
2. Sottoriva A., Kang H., Ma Z., et al. (2015)"A Big Bang model of human colorectal tumor growth". Nat. Genet. 47 :209–216.
3. Gimba E.R. and Tilli T.M.(2013)" Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways". Cancer Lett. 331:11–17.
4. Sodek J. , Ganss B. and McKee M.D.(2000) Osteopontin, Crit. Rev. Oral Biol. Med. 11:279–303.
5. Bandopadhyay M. , Bulbule A. , Butti R. , et al.(2014)" Osteopontin as a therapeutic target for cancer, Expert Opin. Ther. Targets 18: 883–895.
6. Weber G.F. , Lett G.S., Haubein N.C. (2010)."Osteopontin is amarker for cancer aggressiveness and patient survival". Br. J. Cancer 103:861–869.
7. Cao DX, Li ZJ, Jiang XO, et al.(2012)." Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers". World J Gastroenterol;18(30):3923-3930 Carcinoma". Cancer;83:2521. 8. Kiefer MC, Bauer DM and Barr PJ (1989). "The cDNA and derived amino acid sequence for human osteopontin.". Nucleic Acids Res. 17 (1): 3306 . doi:10.1093 /nar/17.8.3306 . 9. Crosby AH, Edwards SJ, Murray JC and Dixon MJ (1995). "Genomic organization of the human osteopontin gene : exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfect typeII". Genomics. 27 (1):155160 . 10. Merry K, Dodds R, Littlewood A and Gowen M (1993). "Expression of Osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone". J Cell Sci. 104 (4): 1013–1020. 11. Nakashima K, Zhou X, Kunkel G et al.(2002). "The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation" . Cell. 108 (1):1729. 12. Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G (1997). "Osf2/Cbfa1:a transcriptional activator of osteoblast differentiation" . Cell. 89 (1): 747–754. 13. Yucha C and Guthrie D (2003). "Renal homeostasis of calcium" . Nephrol Nurs J. 30 (1): 755–764. 14. Chang P.L. and Prince C.W. (1991) "1α,25-Dihydroxyvitamin D3 Stimulates Synthesis and Secretion of Nonphosphorylated Osteopontin (Secreted Phosphoprotein 1) in Mouse JB6 Epidermal Cells" Cancer Research 51.NO.8.PP: 2144-2150.
15. Fatherazi S, Matsa-Dunn D, Foster BL et al. (2009). "Phosphate regulates osteopontin gene transcription" . JDentRes. 88 (1):39-44.
16. Guo H, Cai CQ, Schroeder RA and Kuo PC (2001). "Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages" . JImmunol . 166 (1):1079-1086.
17. Ricardo SD, Franzoni DF, Roesener CD, Crisman JM and Diamond JR (2000). "Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells" . Am J Physiol Renal Physiol. 278 (1): 708–716. 18. Sodhi CP, Phadke SA, Batlle D and Sahai A (2001). "Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin". Am J Physiol Renal Physiol . 280 (1):667674. 19. Briones-Orta M.A. , Avendaño-Vázquez S. , Aparicio-Bautista D.I. et al.(2017) "Osteopontin splice variants and polymorphisms in cancer progression and prognosis." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1868(1): 93-108.A. 20. Ramchandani D and Weber GF. (2013)" An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer". Oncol Rep.;30(4):1860-8. doi: 10.3892/or.2013.2632. Epub 2013 Jul 23. 21. He, L., and Wang, Y. (2016). "Association of OPN rs11730582 polymorphism with cancer risk: a meta-analysis". OncoTargets and Therapy, 9, 1275–1280. 22. Sherry S.T., Ward M.H., Kholodov M., et al.(2001) "dbSNP: theNCBI database of genetic variation, Nucleic Acids Res. 29:308–311. 23. Schultz J., Lorenz P., Ibrahim S.M., et al. (2009)." The functional−443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor". Mol.Carcinog. 48 :14–23. 24. Liu Y., Lei H. , Zhang J., Wang J., Li K. and Dong W. (2015)"Associations between the genetic polymorphisms of osteopontin promoter and susceptibility to cancer in Chinese population: a meta-analysis". PLoS One 10 , e0135318. 25. Yang G. , Peng X. , Guo P. and Yang G.(2015) "Association of osteopontin polymorphism with cancer risk: a meta-analysis". Int. J. Clin. Exp. Med. 8 :20911–20917. | ||||
|
Statistics Article View: 156 PDF Download: 218 |
||||
